Zacks Investment Research Upgrades DiaMedica Therapeutics (DMCAF) to “Buy”

Zacks Investment Research upgraded shares of DiaMedica Therapeutics (OTCMKTS:DMCAF) from a hold rating to a buy rating in a report issued on Monday morning. Zacks Investment Research currently has $0.50 price target on the stock. Zacks Investment Research also issued estimates for DiaMedica Therapeutics’ FY2018 earnings at ($0.03) EPS, FY2019 earnings at ($0.04) EPS, FY2021 earnings at $0.11 EPS and FY2022 earnings at $0.16 EPS.

According to Zacks, “DiaMedica Therapeutics Inc. is a biopharmaceutical company. It engages in the development of novel recombinant proteins and monoclonal antibodies. The companys lead product principally consists DM199, a recombinant human tissue kallikrein-1 protein. It operates primarily in the United States and Canada. DiaMedica Therapeutics Inc. is headquartered in Minneapolis, Minnesota. “

DMCAF stock opened at $0.44 on Monday. DiaMedica Therapeutics has a 12-month low of $0.18 and a 12-month high of $0.48.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of novel recombinant proteins and monoclonal antibodies. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein with a focus on acute vascular diseases, such as acute ischemic stroke and kidney injury indications.

Get a free copy of the Zacks research report on DiaMedica Therapeutics (DMCAF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply